SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting
2024年6月24日 - 10:47PM
SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company
and a leader in data-driven medicine, is pleased to announce that
its annual general meeting of shareholders (the
“
AGM”) was held at the Company’s headquarters, La
Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST
(8:00 a.m. EDT).
The Company’s shareholders have adopted all
proposals presented at the AGM. The AGM minutes and detailed voting
results by agenda item will be published on the Company’s website
in the Investors section. They will also be filed with the U.S.
Securities and Exchange Commission on Form 6-K.
The Company would like to thank all shareholders
represented for their votes and their valued commitment and
support.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.com and connect on LinkedIn.
About SOPHiA GENETICSSOPHiA
GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology
company on a mission to expand access to data-driven medicine by
using AI to deliver world-class care to patients with cancer and
rare disorders across the globe. It is the creator of SOPHiA DDM™,
a platform that analyzes complex genomic and multimodal data and
generates real-time, actionable insights for a broad global network
of hospital, laboratory, and biopharma institutions. For more
information, visit SOPHiAGENETICS.com and connect with us on
LinkedIn.
Forward-Looking StatementsThis
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding SOPHiA GENETICS’ future results of operations and
financial position, business strategy, products and technology,
partnerships and collaborations, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on SOPHiA GENETICS’
management’s beliefs and assumptions and on information currently
available to the company’s management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in the
company’s filings with the U.S. Securities and Exchange Commission.
No assurance can be given that such future results will be
achieved. Such forward-looking statements contained in this press
release speak only as of its date. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
the company’s expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investors Contact:Kellen
SangerIR@sophiagenetics.com
Media Contact:Kelly
Katapodismedia@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
過去 株価チャート
から 8 2024 まで 9 2024
Sophia Genetics (NASDAQ:SOPH)
過去 株価チャート
から 9 2023 まで 9 2024